Literature DB >> 26369359

Is it time to think about the sodium glucose co-transporter 2 sympathetically?

Rosemary H Elliott1, Vance B Matthews1, Caroline Rudnicka2, Markus P Schlaich1.   

Abstract

Disturbances in glucose homeostasis are a key feature of the metabolic syndrome and type 2 diabetes. Renal glucose reabsorption is an important factor in glycaemic control. Glucose reabsorption in the proximal tubules is mediated by the sodium glucose co-transporter 2. The capacity for glucose reabsorption is increased in type 2 diabetes and contributes significantly to hyperglycaemia and impaired glucose control. Understanding the mechanisms underpinning the regulation of the sodium glucose co-transporter 2 is therefore of high clinical relevance. However, despite recent advances in the field and the availability of pharmacological inhibitors of this glucose transporter for the treatment of type 2 diabetes, the mechanisms that regulate sodium glucose co-transporter 2 expression are not fully understood. The sympathetic nervous system is an important modulator of glucose homeostasis, and sympathetic hyperactivity is a characteristic feature of obesity, the metabolic syndrome and type 2 diabetes. Sympathetic inhibition either achieved pharmacologically or by renal sympathetic denervation has been associated with improved glucose control. Importantly, sympathetic nerves innervate the proximal tubules of the kidney where they have been shown to regulate the expression of other transporters such as the sodium hydrogen exchanger 3. This review aims to explore the evidence for the regulation of sodium glucose co-transporter 2-mediated glucose reabsorption by the sympathetic nervous system.
© 2015 Asian Pacific Society of Nephrology.

Entities:  

Keywords:  glucose; norepinephrine; sodium glucose co-transporter 2; sympathetic nervous system; type 2 diabetes mellitus

Mesh:

Substances:

Year:  2016        PMID: 26369359     DOI: 10.1111/nep.12620

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  10 in total

Review 1.  Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure.

Authors:  André J Scheen
Journal:  Curr Cardiol Rep       Date:  2019-06-21       Impact factor: 2.931

2.  Increased waist-to-hip ratio is associated with decreased urine glucose excretion in adults with no history of diabetes.

Authors:  Juan Chen; Shanhu Qiu; Haijian Guo; Wei Li; Zilin Sun
Journal:  Endocrine       Date:  2018-10-31       Impact factor: 3.633

3.  Enhanced Expression and Function of Renal SGLT2 (Sodium-Glucose Cotransporter 2) in Heart Failure: Role of Renal Nerves.

Authors:  Kenichi Katsurada; Shyam S Nandi; Neeru M Sharma; Kaushik P Patel
Journal:  Circ Heart Fail       Date:  2021-11-18       Impact factor: 8.790

4.  Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice.

Authors:  Thiquynhnga Nguyen; Song Wen; Min Gong; Xinlu Yuan; Dongxiang Xu; Chaoxun Wang; Jianlan Jin; Ligang Zhou
Journal:  Diabetes Metab Syndr Obes       Date:  2020-08-05       Impact factor: 3.168

5.  Octopamine Underlies the Counter-Regulatory Response to a Glucose Deficit in Honeybees (Apis mellifera).

Authors:  Christina Buckemüller; Oliver Siehler; Josefine Göbel; Richard Zeumer; Anja Ölschläger; Dorothea Eisenhardt
Journal:  Front Syst Neurosci       Date:  2017-08-30

6.  Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.

Authors:  Atsushi Tanaka; Michio Shimabukuro; Yosuke Okada; Isao Taguchi; Minako Yamaoka-Tojo; Hirofumi Tomiyama; Hiroki Teragawa; Seigo Sugiyama; Hisako Yoshida; Yasunori Sato; Atsushi Kawaguchi; Yumi Ikehara; Noritaka Machii; Tatsuya Maruhashi; Kosuke R Shima; Toshinari Takamura; Yasushi Matsuzawa; Kazuo Kimura; Masashi Sakuma; Jun-Ichi Oyama; Teruo Inoue; Yukihito Higashi; Shinichiro Ueda; Koichi Node
Journal:  Cardiovasc Diabetol       Date:  2017-04-12       Impact factor: 9.951

Review 7.  Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition.

Authors:  Lakshini Y Herat; Jennifer Matthews; Omar Azzam; Markus P Schlaich; Vance B Matthews
Journal:  Curr Hypertens Rep       Date:  2022-03-02       Impact factor: 5.369

Review 8.  A Systematic Review of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Sympathetic Nervous System Inhibition: An Underrated Mechanism of Cardiorenal Protection.

Authors:  Shafaat Raza; Stephen Osasan; Sudiksha Sethia; Tayyaba Batool; Zarna Bambhroliya; Joel Sandrugu; Michael Lowe; Oluwasemilore Okunlola; Pousette Hamid
Journal:  Cureus       Date:  2022-06-25

9.  SGLT2 Inhibitor-Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection.

Authors:  Lakshini Y Herat; Aaron L Magno; Caroline Rudnicka; Jana Hricova; Revathy Carnagarin; Natalie C Ward; Angelique Arcambal; Marcio G Kiuchi; Geoff A Head; Markus P Schlaich; Vance B Matthews
Journal:  JACC Basic Transl Sci       Date:  2020-01-29

Review 10.  Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection.

Authors:  Yi-Chou Hou; Cai-Mei Zheng; Tzung-Hai Yen; Kuo-Cheng Lu
Journal:  Int J Mol Sci       Date:  2020-10-22       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.